Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials.
Level 1 - systematic review of randomized trials
Meta-analysis of 90 randomized controlled trials
PubMed 37264945 · doi:10.1161/JAHA.123.029512
What was done
A dose-response meta-analysis of 90 randomized controlled trials encompassing 72,598 participants evaluated the association between daily omega-3 fatty acid intake (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], or both) and changes in blood lipids. Investigators utilized random-effects 1-stage cubic spline regression models to model the shape and trajectory of dose-response relationships.
What was found
The abstract does not report exact effect estimates, point reductions, or confidence intervals. It identified approximately linear dose-response reductions in triglycerides and non-HDL cholesterol across the general population, which were more pronounced in individuals with hyperlipidemia or overweight/obesity receiving medium-to-high doses (>2 g/day). Conversely, associations with low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were nonlinear, exhibiting J-shaped dose-response curves.
Why it matters
These findings delineate the dose-dependent lipid effects of omega-3 supplementation, clarifying that substantial triglyceride and non-HDL cholesterol reductions primarily manifest at intakes exceeding 2 g/day.
Limits
The abstract provides no numerical effect sizes or confidence intervals for any lipid fraction. It does not stratify findings by EPA versus DHA monotherapy formulations, baseline statin use, trial duration, or clinical cardiovascular outcome endpoints.
Cited by
- supports Omega-3 fish oils lower triglycerides, whereas omega-6 polyunsaturated fatty acids promote inflammation.